Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
Total Valuation
Castle Biosciences has a market cap or net worth of $479.86M. The enterprise value is $323.45M.
Market Cap$479.86M
Enterprise Value$323.45M
Share Statistics
Castle Biosciences has 28,872,314 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,872,314
Owned by Insiders2.72%
Owned by Institutions0.25%
Financial Efficiency
Castle Biosciences’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 1.52%.
Return on Equity (ROE)0.04
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)1.52%
Return on Capital Employed (ROCE)0.02
Revenue Per Employee423.56K
Profits Per Employee23.27K
Employee Count784
Asset Turnover0.63
Inventory Turnover7.40
Valuation Ratios
The current PE Ratio of Castle Biosciences is 40.57. Castle Biosciences’s PEG ratio is -0.31.
PE Ratio40.57
PS Ratio0.00
PB Ratio1.62
Price to Fair Value1.62
Price to FCF20.26
Price to Operating Cash Flow11.41
PEG Ratio-0.31
Income Statement
In the last 12 months, Castle Biosciences had revenue of 332.07M and earned 18.25M in profits. Earnings per share was 0.66.
Revenue332.07M
Gross Profit271.86M
Operating Income8.67M
Pretax Income21.56M
Net Income18.25M
EBITDA38.14M
Earnings Per Share (EPS)0.66
Cash Flow
In the last 12 months, operating cash flow was 65.67M and capital expenditures -23.91M, giving a free cash flow of 41.75M billion.
Operating Cash Flow65.67M
Free Cash Flow41.75M
Free Cash Flow per Share1.45
Dividends & Yields
Castle Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.55
52-Week Price Change-30.78%
50-Day Moving Average19.93
200-Day Moving Average26.52
Relative Strength Index (RSI)31.30
Average Volume (3m)439.89K
Important Dates
Castle Biosciences upcoming earnings date is Aug 11, 2025, TBA Not Confirmed.
Last Earnings DateMay 5, 2025
Next Earnings DateAug 11, 2025
Ex-Dividend Date―
Financial Position
Castle Biosciences as a current ratio of 7.29, with Debt / Equity ratio of 5.87%
Current Ratio7.29
Quick Ratio7.13
Debt to Market Cap0.01
Net Debt to EBITDA-2.45
Interest Coverage Ratio15.03
Taxes
In the past 12 months, Castle Biosciences has paid 3.32M in taxes.
Income Tax3.32M
Effective Tax Rate0.15
Enterprise Valuation
Castle Biosciences EV to EBITDA ratio is 16.96, with an EV/FCF ratio of 17.70.
EV to Sales1.95
EV to EBITDA16.96
EV to Free Cash Flow17.70
EV to Operating Cash Flow9.97
Balance Sheet
Castle Biosciences has $275.15M in cash and marketable securities with $25.84M in debt, giving a net cash position of -$249.31M billion.
Cash & Marketable Securities$275.15M
Total Debt$25.84M
Net Cash-$249.31M
Net Cash Per Share-$8.63
Tangible Book Value Per Share$12.59
Margins
Gross margin is 85.88%, with operating margin of 2.61%, and net profit margin of 5.49%.
Gross Margin85.88%
Operating Margin2.61%
Pretax Margin6.49%
Net Profit Margin5.49%
EBITDA Margin11.48%
EBIT Margin6.67%
Analyst Forecast
The average price target for Castle Biosciences is $35.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$35.75
Price Target Upside113.05% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast38.43%
EPS Growth Forecast86.19%